| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Outline of Final Research Achievements |
Advanced gastric cancer (GC) frequently recurs because of undetected micrometastases even after curative resection. Peritoneal metastasis has been the most frequent recurrent pattern after gastrectomy and is incurable. We conducted a recurrence pattern-specific transcriptome analysis and synaptotagmin VIII (SYT8) was identified as a candidate biomarker specific to peritoneal metastasis. Expression levels of SYT8 mRNA in GC tissues were elevated in patients with peritoneal recurrence or metastasis. SYT8 levels served as an independent prognostic marker for peritoneal recurrence-free survival of patients with stage II/III GC. Inhibition of SYT8 by GC cells correlated with decreased invasion, migration, and fluorouracil resistance. Intraperitoneal administration of SYT8-siRNA inhibited the growth of peritoneal nodules and prolonged survival of mice engrafted with GC cells. SYT8 represents a promising target for the detection, prediction and treatment of peritoneal metastasis of GC.
|
